Kornimate/medical-research-clean huggingface dataset:
functional brain imaging and psychological testing in women with chronic pelvic pain

Conditions: Pelvis Pain Chronic; Endometriosis of Uterus

Summary: functional magnetic resonance imaging in women with chronic pelvic pain using arterial spin labelling, functional connectivity, diffusion tensor imaging and magnetic resonance spectroscopy.

multimodal magnetic resonance neuroimaging will be utilised. arterial spin labelling is tightly coupled with cerebral metabolism and can be used as a marker of neural activity. resting state magnetic resonance imaging which measures synchronous activity across the brain, allows detection of functional connectivity of intrinsic brain network. diffusion tensor imaging detects the anisotropic water diffusion in axonal fibres can provide information on connectivity and fibre tracts. magnetic resonance spectroscopy would enable the levels of neurotransmitter to be elucidated.

Eligibility criteria:
inclusion criteria: * chronic pelvic pain * endometriosis exclusion criteria: * contraindication to magnetic resonance imaging

Keywords: chronic pelvic pain endometriosis
tayside rehabilitation in bronchiectasis exacerbations (tribe) : a randomized controlled trial

Conditions: Bronchiectasis

Summary: pulmonary rehabilitation is well established as a treatment in copd. after exacerbations of copd, rehabilitation is associated with reduced frequency of exacerbations and improved exercise capacity. no data are available in bronchiectasis. this study will randomly assign patients with bronchiectasis exacerbations to pulmonary rehabilitation or standard care. the hypothesis is that exercise capacity will be improved by pulmonary rehabilitation at 8 weeks.

background: pulmonary rehabilitation is an effective treatment after exacerbations of copd to prevent future exacerbations and to improve breathlessness and quality of life. its effectiveness after exacerbations of bronchiectasis has never been demonstrated. aims: to determine if a 6 week course of pulmonary rehabilitation improves exercise capacity at 8 weeks after exacerbation. study design: randomised controlled trial. methods: the study will take place in nhs tayside. 40 patients with a history of bronchiectasis confirmed by hrct will be included. patients will be monitored using diary cards for exacerbations. at the onset of an exacerbation patients will be treated with a standard 14 day course of antibiotic therapy and randomised to one of two arms: pulmonary rehabilitation or standard care. patients randomised to pulmonary rehabilitation will undergo a 6 week course of supervised pulmonary rehabilitation. patients will undergo study assessments (6-minute walk test, quality of life questionnaires, pulmonary function tests (fev1, fvc, fef 25-75), symptoms recorded by symptom diaries and sputum microbiology).assessments will be performed at the start and end of exacerbations, at 6-8 weeks post exacerbation (after completion of pulmonary rehabilitation in patients randomised to rehabilitation) and at 12 weeks. outcome: the primary outcome is 6 minute walk distance at 8 week post exacerbation expected conclusion: we will determine the effectiveness of pulmonary rehabilitation after exacerbations of bronchiectasis.

Eligibility criteria:
inclusion criteria: bronchiectasis confirmed on high resolution ct scan clinical bronchiectasis confirmed by a respiratory physician. documented exacerbation within the last year. independently mobile - i.e. able to undertake pulmonary rehabilitation exclusion criteria: * inability to give informed consent to participate * age \<18 years * primary diagnosis of chronic obstructive pulmonary disease * significant comorbidity that would limit the ability to undertake pulmonary rehabilitation - i.e. cerebrovascular, cardiovascular or musculoskeletal disease. * cystic fibrosis * aortic aneurysm * recent myocardial infarction (within previous year)or unstable angina

Keywords: bronchiectasis rehabilitation exercise exacerbations
optical biopsy in gynecological surgery

Conditions: Gynecologic Surgical Procedures

Summary: optical biopsy is a new technology that generates a real-time, cell-based, high-resolution view and analysis of tissues. observation is instantaneous and non-invasive. this allows reliable and fast diagnosis which facilitates decision making as well as patient management. the investigator have already conducted a feasibility study on the use of this new technology to evaluate ovarian and tubal pre-cancerous lesions in laparoscopy. in this new study, he wants to continue investigations, expand its use to other gynecological pathologies, and demonstrate the benefit of such a non-invasive technology in gynecology on the one hand in the diagnosis of lesions but also to appreciate the margins as accurately as possible surgical excision of tumors and / or endometriosis lesions. the investigator have set up a prospective monocentric descriptive study. the hypothesis is that optical biopsy by cellvizio® allows to observe in real time microscopically tissues and to characterize them in the field of gynecological surgery


Eligibility criteria:
inclusion criteria: * women aged 18 years or more * informed and signed consent * planned surgery under laparoscopy and included in the list below: * unilateral or bilateral salpingectomy * hysterectomy * ovariectomy * surgery of endometriosis * surgery for cancer of the cervix, endometrium, ovaries exclusion criteria: * interview revealing disorder entailing unacceptable risk of postoperative complications: coagulation disorder, immune system disorder, evolutive disease, etc. * pregnancy or desire of pregnancy during the study period, breastfeeding * hypersensitivity to fluorescein or any of its excipients * history of life-threatening reaction during angiography * known allergic reactions and hypersensitivity * severe asthma, heart and / or lung disease, diabetes * person on beta-blocker treatment * inability to understand information provided * not covered by a national health insurance scheme, prisoner or under administrative supervision

Keywords: salpingectomy cellvizio® optical biopsy unilateral or bilateral salpingectomy ovariectomy endometriosis surgery for cervical ovarian cancer
efficacy of indigenously adapted cognitive behavioral therapy for reducing gaming addiction among adolescents

Conditions: Internet Gaming Disorder

Summary: research evidence identified internet gaming as an emerging problem in youth across the globe and a lot of interventions are being used for managing gaming and associated psychological problems considering cultural aspects. therefore, the present study aims at investigating the efficacy of indigenously adapted cognitive behavior therapy for internet gaming addiction among pakistani youth. for this purpose, adolescents enrolled in 8th-12th grades in elementary and higher secondary schools in twin cities of pakistan. adolescents who scored high on internet gaming disorder in screening will be included in the study and further detailed investigation will be completed by administering semi-structured clinical interviews, coping inventory, self-control, and social connectedness. participants will be divided into 2 groups i.e. experimental and control groups.


Eligibility criteria:
inclusion criteria: 1. adolescents ranging from 13 - 19 years (who, 2013) enrolled in an educational institute in the vicinity of the federal capital area 2. playing internet offline/online games. 3. excessive users who play more than 5-8 hours per day,40 hours per week will be included. 4. playing games for at least the past year. 5. no history of major illness or any other psychological disorder. exclusion criteria: 1. diagnosed prior for any mental or psychological disorder. 2. receiving any psychotherapy or medication for any particular disorder
yoga and vibration training for stress urinary incontinence in women

Conditions: Urinary Incontinence

Summary: this study aimed to compare the effects of yoga and whole body vibration training on pelvic floor muscle strength, severity of urinary symptoms and ui-related quality of life in women with ui. the intervention period for the study was determined as 6 weeks. it has been decided that yoga practice will be done 3 times a week for 45 minutes, and whole body vibration training will be done for 45-55 minutes. the home exercise group will perform the planned exercise protocol every day for 6 weeks. the results of the study will be evaluated by statistical analysis as a result of the interventions and evaluations.


Eligibility criteria:
inclusion criteria: * between the ages of 20-60, * patients with sui or mix ui with a predominant sui component, * patients who have not received treatment with any physical therapy modality in the last 3 months, * patients who signed the informed consent form. exclusion criteria: * those with neurological diseases that may cause incontinence * those with prolapse * those using intrauterine devices * obesity (bmi \>30) * patients with serious systemic diseases that prevent them from exercising (cardiovascular disease, copd, cvo and/or cancer) * patients with pure urge or mixed ui with a predominant urge component * patients with a history of thrombosis * patients who engage in high-intensity sports activities for at least half an hour at least twice a week (tennis, aerobic exercise, running, exercises with body weight). * patients with neurological or vestibular disease that may cause balance disorders * patients with grade 3 or 4 knee and/or hip osteoarthritis * patients with a history of knee and/or hip joint replacement surgery * patients with kidney or gallbladder stones * patients with acute disc herniation or spondylolisthesis

Keywords: urinary incontinence yoga whole body vibration training pelvic floor muscle quality of life
garcinia mangostana extracts in the management of weight loss

Conditions: Severe Obesity

Summary: obesity is one of the greatest public health challenges of the 21st century. its prevalence has tripled in many countries of the european region since the 1980s, and the numbers of those affected continue to rise at an alarming rate. in addition to causing various physical disabilities and psychological problems, excess weight drastically increases a person's risk of developing a number of noncommunicable diseases including cardiovascular disease, cancer and diabetes, in association or not to metabolic syndrome. the risk of developing more than one of these diseases (co-morbidity) also increases with increasing body weight. every year a growing number of patient tend to suffer of more severe obesity and difficulty in losing weight even with a restricted diet and exercise. garcinia mangostana (sphaeranthus indicus extract) has known for its antioxidant properties; new evidence point out some promising effects in the prevention of lipogenesis and the promotion of lipolysis . currently in the scientific literature there is only one paper, by stern et al., showing the association of garcinia mangostana assumption in low-calorie diet. this work has demonstrated a significant reduction in weight loss , compared to the placebo group,due to the use of garcinia mangostana. aim of the present study is the evaluation of safety and efficacy of weight loss in severe obese patients. also cardiometabolic parameters and flogosys serum indicators will be evaluated before and after 6 month therapy of low calory diet alone or in association with garcinia mangostana extract.

after the screening visit for the evaluation of the inclusion / exclusion criteria and sign informed consent(visit 1), each patient will be randomized (visit 2; time 0; baseline) (1: 1) to receive two different treatment for the duration of 26 weeks: 1. low-calorie balanced diet consistent exercise (control group) 2. balanced low-calorie diet and regular exercise in combination with the assumption of garcinia mangostana (treatment group) throughout the duration of the study, every eight weeks, unless otherwise indicated from the specialists, for each subject was expected a nutritional and an endocrinological visit with a anthropometric parameter check (body composition) and compliance to therapy (dietary / physical activity diary). also a bood sample test was performed to evaluate electrocardiogram, lipid profile, glucose tolerance, hormonal parameters, inflammatory and bone markers.

Eligibility criteria:
inclusion criteria: * obesity: bmi \>35 kg/m2. * stable medical therapy for comorbidities from at least 6 months exclusion criteria: * hormonal replacement therapy * hyperprolactinaemia and /or other endocrine hypothalamic-pituitary diseases (empty sella syndrome and expansive pituitary disorders evaluated by mri) * any other condition that medical judgment precludes patient safety
molecular mechanisms of the development of precancerous and cancerous lesions of the oral cavity

Conditions: Oral Lichen Planus; Oral Squamous Cell Carcinoma

Summary: the aim of this study was to examine molecular alterations on the protein level in lesions of oral lichen planus (olp), oral squamous cell carcinoma (oscc) and healthy mucosa. global protein profiling methods based on liquid chromatography coupled to mass spectrometry were used, with a special emphasis on evaluation of deregulated extracellular matrix molecules expression, as well as on analyses of insulin-like growtg factor 2 (ig2f) and insulin-like growth factor 2 receptor (igfr2) expression in healthy mucosa, olp and oscc tissues by comparative semiquantitative immunohistochemistry. mass spectrometry based proteomics profiling of healthy mucosa, olp and oscc tissues (and accompanied histologically unaltered tissues, respectively) identified 55 extracellular matrix proteins. twenty among identified proteins were common to all groups of samples. statistically significant difference between final igf2 and igf2r irs scores in favour to igf2r may further corroborate the ig2fr antitumor role in olp and oscc where it acts as a negative regulator of igf2 activity.

although olp is categorised as a precancerous condition associated with a significantly increased risk of oral cancer, molecular pathophysiology of olp and its potential for malignant transformation in oscc are poorly understood and remain controversial. development of new analytical methods enhances research in the field of malignant disorders. identification of novel biomarkers help in the diagnostic process, pre-symptomatic interventions or prediction of treatment response. proteomics based on mass spectrometry enables analysis of novel, putative biomarkers. in this study, proteomics was used to analyse in more details extracellular matrix (ecm) proteins and proteins related to ecm signalization which have a well-established role in malignant transformation and invasion of tumor cells. igf2 and igf2r are known biomarkers in cellular metabolism,but their role in oral precancerous lesions, namely oral lichen planus (olp) as well as in oral squamous cell carcinoma (oscc) has not been explored so far. the second aim of our study was to analyse ig2f and igfr2 expression in oral lichen planus and oral squamous cell carcinoma tissues by comparative semiquantitative immunohistochemistry

Eligibility criteria:
inclusion criteria: * histopathologically confirmed oral lichen planus and oral squamous cell carcinoma * healthy volunteers referred for alveolotomy exclusion criteria: * non-consent patients * previously treated oscc * patients under immunosuppressive therapy
cortical excitability assessment using paired pulses

Conditions: Focal Epilepsy

Summary: the identification of the epileptogenic zone (ez) during pharmacoresistant focal epilepsy presurgical assessment frequently requires intracranial recordings like stereo-electroencephalography (seeg). cortical direct electrical stimulation (des) is commonly used during seeg for functional mapping or to induce seizure. however, the recording of seizures is sometimes insufficient to circumscribe the ez and development of new biomarkers is necessary. the cortex within the ez is thought to be hyperexcitable. the "paired pulses" paradigm, using transcranial magnetic stimulation (tms), allows determining the hemispheric cortical excitability level. the investigators hypothesize that paired pulses des during seeg could provide useful information for ez identification.


Eligibility criteria:
inclusion criteria: * age above 18 years old * pharmacoresistant focal epilepsy patients undergoing a stereo-electroencephalographic recording * provide written consent to the study after receiving clear information * be a beneficiary or member of health insurance plan exclusion criteria: patient with contraindication for mri scanning * pregnancy * prohibition on participation in other research, apart from any other non-interventional research

Keywords: pharmacoresistant focal epilepsy cortical excitability paired pulses tms seeg des
misoprostol for the treatment of incomplete abortion

Conditions: Abortion, Incomplete

Summary: this randomized study will examine the efficacy, safety and acceptability of misoprostol for treatment of incomplete abortion. women diagnosed with incomplete abortion will be randomized to receive one of the following regimens: in tanzania and mozambique: 1. 600 mcg of oral misoprostol in one dose, or 2. standard surgical treatment (mva) in moldova and madagascar: 1. 600 mcg of oral misoprostol in one dose, or 2. 400 mcg of sublingual misoprostol in one dose. in burkina faso and vietnam: 1. 400 mcg of sublingual misoprostol in one dose. we hypothesize that treatment of incomplete abortion with either 400 mcg sublingual misoprostol, 600 mcg oral misoprostol or mva are equally effective in evacuating the uterus.


Eligibility criteria:
inclusion criteria: * if no ultrasound used: 1. past or present history of vaginal bleeding during pregnancy; and 2. open cervical os. * if ultrasound used: 1. past or present history of vaginal bleeding during pregnancy; and 2. evidence of incomplete abortion with substantial debris in the uterus. all women would have been advised to have surgical evacuation of the uterus if misoprostol was not available. * willing to provide contact information for purposes of follow-up. * in tanzania: 18 years of age or over or parental permission * in mozambique: 21 years of age or over or parental permission * in moldova: 18 years of age or over * in madagascar: 18 years of age or parental permission * in vietnam: reproductive age exclusion criteria: * contraindications to the study drug; * uterine size larger than 12 weeks l.m.p. at time of presentation for care. * signs of severe infection, defined as at least one of the following of: 1. foul smelling discharge, 2. fever \> 39 degrees c , 3. pulse \>110/min;

Keywords: misoprostol incomplete abortion sublingual postabortion care mva
evaluation of anti-platelet factor 4/heparin antibodies in hemodialysis patients

Conditions: End Stage Renal Disease

Summary: to characterize the gore® hybrid vascular graft as compared to non-heparin bonded synthetic vascular grafts in terms of the prevalence and persistence of anti-platelet factor 4 / heparin antibodies (anti-pf4 / h antibodies).


Eligibility criteria:
inclusion criteria: * the patient is not a candidate for a native fistula. * the patient requires the creation of an upper arm vascular access graft for hemodialysis secondary to a diagnosis of end-stage renal disease. * the patient has been on hemodialysis for ≥1 month. exclusion criteria: * the patient is scheduled for a different surgical procedure within 30 days post index procedure. * the patient has a known hypercoagulable disorder or bleeding disorder. * the patient has had a previous instance of heparin induced thrombocytopenia type ii (hit type ii) or has known sensitivity to heparin.

Keywords: hemodialysis end stage renal disease vascular graft
an open label, single dose, three part study to assess the effects of rolapitant (2 mg/ml iv solution) on the pharmacokinetics of digoxin; sulfasalazine; and the cooperstown cocktail (midazolam, omeprazole, warfarin, caffeine, and dextromethorphan in healthy subjects

Conditions: Chemotherapy-induced Nausea and Vomiting

Summary: the objective of this open label study is to evaluate effects of rolapitant iv solution, and its metabolite, on the pharmacokinetics (pk) of the p-gp substrate (digoxin), the bcrp substrate (sulfasalazine), and multiple cytochrome p450 (cyp) probe substrates in a healthy adult population.

* part a will compare the pk of oral digoxin alone and in combination with an iv infusion of rolapitant. * part b will compare the pk of an oral dose of sulfasalazine alone to the pk of an oral dose of sulfasalazine in combination with an iv infusion of rolapitant * part c will compare the pk of an oral dose of the cooperstown cocktail (midazolam, omeprazole, warfarin, caffeine, and dextromethorphan) alone and when given in combination with an iv infusion of rolapitant.

Eligibility criteria:
main inclusion criteria: * subjects must be healthy males or females aged 18 to 55 years (inclusive) * female subjects (of childbearing potential) must have a negative pregnancy test at screening and on day -1 * female subjects of childbearing potential must agree to use an accepted method of birth control (excluding hormonal birth control methods) before visit 1 and to continue its use during the study and for at least 30 days after the final dose * subjects must have a body mass index (bmi) from 18.5 to 32.0 kg/m2 (inclusive) and a weight of ≥50 kg at screening * subjects must be capable of understanding the informed consent after the risks and benefits of the study have been explained; subjects must be able to sign a written informed consent and be willing to comply with the protocol requirements * subjects must be in general good health as determined by the investigator based on pre-study medical and surgical history, physical examination \[pe\], and clinical laboratory tests main exclusion criteria: * subjects who have participated in another investigational study within 30 days or 5 half-lives of the test drug's biologic activity, whichever is longer, before the time of the first study dose * subjects who have a history of relevant allergies (including asthma, food, or drug allergies) as determined by the investigator * subjects who have had significant blood loss, or have donated or received ≥1 units (450 ml) of blood, within 30 days before the first study dose * subjects who have a history of hypersensitivity to rolapitant iv or any of its excipients or who have participated in a previous rolapitant study within 6 months prior to administration of the first dose of study drug (day 1) * subjects with poor venous access and/or cannot tolerate venipuncture * subjects with a history of significant complications or anxiety associated with the iv administration of medications that, in the opinion of the investigator, could make the subject * subjects who have a history of hypersensitivity to sulfasalazine (part b only).
correlation between five asthma control questionnaires

Conditions: Asthma

Summary: this observational study aims to assess the correlation between many questionnaires designed to assess the level of control of asthma. the five questionnaires will be submitted, at the same time and in a random order, to asthma patients. some other parameters will be recorded (e.g. lung function, epidemiological data). the hypothesis is that the results of the questionnaires will be the same. if not, we will try to understand why. the investigators will include 100 patients, stratified with relation to their level of asthma severity (25 patients for each level of severity - described by the gina guidelines).


Eligibility criteria:
inclusion criteria: * diagnosis of asthma confirmed by a pulmonologist * patient have had a lung function testing on the same day than the questionnaires are fulfilled. * age equal or upper than 18 years * agreement to participate to this study exclusion criteria: * age under 18 years * refusal to participate to this study

Keywords: asthma questionnaires